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a  b  s  t  r  a  c  t
Honeybee  stings  are  a severe  public  health  problem.  Bee  venom  contains  a series  of active  components,
including  enzymes,  peptides,  and  biogenic  amines.  The  local  reactions  observed  after  envenoming  include
a typical  inﬂammatory  response  and pain.  Honeybee  venom  contains  some  well-known  polycationic  pep-
tides, such as  Melittin,  Apamin,  MCD  peptide,  Cardiopep,  and  Tertiapin.  Secapin  in honeybee  venom  was
described  38  years  ago,  yet  almost  nothing  is known  about  its  action.  A  novel,  variant  form  of  this  pep-
tide  was  isolated  from  the  venom  of  Africanized  honeybees  (Apis  mellifera).  This  novel  peptide,  named
Secapin-2,  is 25 amino  acid  residues  long.  Conformational  analyses  using  circular  dichroism  and  molec-
ular  dynamics  simulations  revealed  a secondary  structure  rich  in  strands  and  turns,  stabilized  by  an
intramolecular  disulﬁde  bridge.  Biological  assays  indicated  that  Secapin-2  did not  induce  hemolysis,  mast
cell degranulation  or chemotactic  activities.  However,  Secapin-2  caused  potent  dose-related  hyperalgesic
and  edematogenic  responses  in experimental  animals.  To  evaluate  the  roles  of prostanoids  and  lipid  medi-
ators in the  hyperalgesia  and  edema  induced  by  this  peptide,  Indomethacin  and Zileuton  were  used to
inhibit  the  cyclooxygenase  and  lipoxygenase  pathways,  respectively.  The  results  showed  that  Zileuton
partially  blocked  the  hyperalgesia  induced  by  Secapin-2  and  decreased  the  edematogenic  response.  In
contrast,  Indomethacin  did not  interfere  with  these  phenomena.  Zaﬁrlukast,  a leukotriene  receptor  antag-
onist,  blocked  the Secapin-2  induced  hyperalgesia  and  edematogenic  response.  These  results  indicate  that
Secapin-2  induces  inﬂammation  and  pain  through  the  lipoxygenase  pathway  in  both  phenomena.
©  2014  Elsevier  Inc.  All  rights  reserved.ntroduction
The venoms of the social Hymenoptera are complex mixtures
f biologically active compounds, such as low molecular mass
ompounds, peptides, and proteins [17,39]. Peptide toxins usually
onstitute up to 70% of the composition of these venoms. It is well
nown that insect stings on human skin can induce ongoing pain,
yperalgesia (and allodynia), and inﬂammation [10,11]. However,
he mechanisms underlying these responses are poorly studied.
These peptides seem to induce a series of pharmacological
ctions that are observed during envenoming caused by honey-
ee, wasp and ant stings [39]. These actions generally result in a
eries of envenoming processes, such as generalized inﬂammation,
∗ Corresponding author at: CEIS/IBRC-UNESP, Avenue 24-A 1515, Bela Vista,
3506-900 Rio Claro, SP, Brazil. Tel.: +55 19 35264163; fax: +55 19 35264163.
E-mail address: mspalma@rc.unesp.br (M.S. Palma).
ttp://dx.doi.org/10.1016/j.peptides.2014.07.004
196-9781/© 2014 Elsevier Inc. All rights reserved.intravascular hemolysis with increased bilirubin levels, decreased
levels of haptoglobin, hemoglobinuria and thrombocytopenia, dis-
seminated intravascular coagulation, rhabdomyolysis, increased
levels of creatine kinase and aldolase, and acute tubular necrosis,
among others [22,23,29]. These actions complicate the establish-
ment of a proper diagnosis and the choice of a suitable clinical
strategy to overcome the envenoming effects [14,17].
The chemical diversity of the peptides in Hymenoptera ven-
oms, have been exploited by using a combination of techniques
such as high-performance liquid chromatography (HPLC) and mass
spectrometry have been applied to aid the discovery of novel
components of social wasp venoms. For example, this analytical
approach led to the detection of more than 100 different peptides
in the venom of the wasp Polybia paulista [19]. In the wasps’ venom,
different types of inﬂammatory peptides such as mastoparans,
protonectin-like peptides, chemotactic peptides, and kinins were
identiﬁed [16,31,39]. Additionally, in honeybee venoms, the pep-
tide components already reported include Melittin [38] and its
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nalogs [3,24], Apamin [45,46], mast cell degranulating (MCD) pep-
ide [7], Cardiopep [47], Tertiapin [50] and Secapin [25,28], as well
s a few others that have been studied.
Secapin is a polycationic peptide with 25 amino acid residues
hat contains an intramolecular disulﬁde bridge; it represents
pproximately 0.5% of the dry weight of honeybee venom [3,39].
his peptide was originally reported in the venom of an Euro-
ean honeybee (Apis mellifera) race without clear identiﬁcation
f the subspecies [24]; the sequence of this peptide was com-
letely assigned later by two independent groups [35,49]. However,
hese studies did not investigate the biological actions of Secapin.
ecently, a novel, variant form of Secapin was described in the
enom of A. mellifera in China without any functional character-
zation [37]. Until now, this peptide has apparently exhibited no
oxicity in mammals because the administration of high doses
up to 80 mg/kg) had no lethal effects; at this dose, the animals
ere reported to exhibit only signs of sedation within the ﬁrst
5 min  of administration, followed by piloerection and hypother-
ia  [24].
In the present study, a novel form of Secapin that was  isolated
rom the venom of Africanized honeybees is reported; therefore,
he aim of this work was the structural and functional charac-
erization of this novel form, termed Secapin-2, focusing on the
nduction of hyperalgesic and edematogenic effects, as well as on
he mechanisms involved in these phenomena.
aterial and methods
nimals
Male Swiss mice, weighing between 25 and 30 g, were used
hroughout this study. The mice were housed under controlled
umidity at a temperature of 22 ± 1 ◦C and subjected to a 12 h
ight–dark cycle in a sound-attenuated room. Food and water
ere available ad libitum, and the mice were taken to the testing
oom at least 1 day before the experiment. All behavioral test-
ng was performed between 9:00 am and 4:00 pm.  Each mouse
as used only once. All experiments were in accordance with
he guidelines for the ethical use of conscious animals in pain
esearch, published by the International Association for the Study
f Pain [51]. The procedures were approved by the Institutional
nimal Care Committee at São Paulo State University/UNESP cam-
us Rio Claro/SP (CEUA-IB-UNESP-CRC, Protocol n◦ 1984). Efforts
ere made to minimize the number of animals used and their
uffering.
iological material
The venom from Africanized A. mellifera was  obtained from
he apiary at the Institute of Biosciences of Rio Claro – UNESP,
t Rio Claro, SP, southeast Brazil; the venom was milked from
he bees using a device that produces pulsed electric discharges
t the entrance of the nest. The worker bees stimulated by these
ischarges stung a plastic ﬁlm covering a glass plate that was
ositioned at the nest entrance, depositing small liquid droplets
ver the plates. The glass plates containing many droplets of the
iquid venom were then dried under a ﬂow of chilled air (4 ◦C),
nd the dried venom was scraped from the glass plate. The solid
enom was then lyophilized, pooled, and stored at −80 ◦C until
se.
enom fractionationThe peptide fraction was obtained by suspending 5 mg  of the
rude venom from Africanized honeybees (A. mellifera) in 2 mL
f 50% (v/v) acetonitrile (MeCN) with shaking for 15 min  at 4 ◦C.s 59 (2014) 42–52 43
The suspension was then centrifuged at 10,000 × g for 10 min  at
4 ◦C. The supernatant was  collected, pooled, and lyophilized, and
the total peptide fraction was stored at −80 ◦C until use. The pep-
tide fraction was then chromatographed on a Capcell Pack C-18
UG120 column (10 mm × 250 mm,  5 m,  Shisheido) under a linear
gradient from 5 to 60% (v/v) MeCN/H2O [containing 0.1% (v/v) tri-
ﬂuoroacetic acid (TFA)] at a ﬂow rate of 2.0 mL/min for 60 min and
monitored by UV absorption at 214 nm with a UV-DAD detector
(Shimadzu, mod. SPD-M10A). The fractions were manually col-
lected in glass vials and dried using a lyophilizer.
Amino acid sequencing
The amino acids were sequenced using a gas-phase sequencer
PPSQ-21A (Shimadzu) based on automated Edman degradation
chemistry.
Peptide synthesis
The peptides were prepared by stepwise, manual solid-phase
synthesis using N-9-ﬂuorophenylmethoxy-carbonyl (Fmoc) chem-
istry with Novasyn TGS resin (NOVABIOCHEM). The side-chain pro-
tective groups included t-butyl (tBu) for serine, t-butoxycarbonyl
(Boc) for lysine, and -t-butyl ester (OtBu) for aspartic acid. The
side-chain protective group trityl (Trt) was used in the synthe-
sis of the oxidized peptide (with the disulﬁde bridge). Cleavage
of the peptide–resin complexes was  performed by treatment
with triﬂuoroacetic acid/1,2-ethanedithiol/anisole/phenol/water
(82.5:2.5:5:5:5 by volume) at room temperature for 2 h. After
ﬁltering to remove the resin, anhydrous diethyl ether (Sigma)
at 4 ◦C was  added to the soluble material to cause precipita-
tion of the crude peptide, which was  collected as a pellet by
centrifugation at 1000 × g for 15 min  at room temperature. The
crude peptide was solubilized in water and puriﬁed by RP-
HPLC. The peptide with the disulﬁde bridge was  obtained by
air oxidation of the cysteine residues as described elsewhere
[1].
The synthetic peptide was  puriﬁed by high-performance liq-
uid chromatography (HPLC, mod. LC 8A) using a Shim-Pack C-18
Prep-ODS (K) column (30 mm × 250 mm,  15 m,  Shimadzu) under
isocratic elution with 45% (v/v) MeCN/H2O [containing 0.05%
(v/v) TFA] at a ﬂow rate of 10 mL/min. The elution was moni-
tored at 214 nm with a UV-Vis detector (Shimadzu, mod. SPD-20A
Prominence). The fractions were manually collected and dried
using a lyophilizer (Heto). The homogeneity and correctness of
the sequence of the synthetic peptides were assessed using a
gas-phase sequencer PPSQ-21A (Shimadzu) based on automated
Edman degradation chemistry and ESI-MS analysis. The synthetic
peptide was used in all the bioassay protocols.
Mass spectrometry
Mass spectrometric analyses were performed on an Ion
Trap/Time-of-Flight hybrid mass spectrometer (LCMS-IT-TOF) pro-
duced by Shimadzu Co. (Kyoto, Japan). The samples were injected
into the LC–MS system with an autosampler injector at a ﬂow rate
of 0.2 mL/min of 50% (v/v) MeCN. All analyses were performed in
the positive electrospray ionization (ESI+) mode using typical con-
ditions: a CDL temperature of 200 ◦C, a capillary voltage of 4.5 kV,
a cone voltage of 3.5 V, a ﬂow rate of the nebulizer gas (nitrogen)
of approximately 1.5 L/h and a drying gas (nitrogen) ﬂow rate of
100 L/h. The ESI mass spectra were obtained in the continuous
acquisition mode, scanning from m/z 50 to 4000 for 2 min. The
data were acquired and analyzed using LCMS solution software
(SHIMADZU, Kyoto, Japan).
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ircular dichroism measurements
To evaluate the conformational changes in the peptides induced
y different membrane-mimetic environments, CD spectra were
btained at a peptide concentration of 20 M in either bi-distilled
ater, 40% (v/v) 2,2,2-triﬂuoroethanol (TFE)/water, or sodium
odecyl sulfate solutions (SDS) above and below the critical micelle
oncentration (CMC) of SDS (8 mM and 165 M SDS, respectively).
he CD spectra were recorded from 260 to 190 nm with a Jasco-815
pectropolarimeter (JASCO International Co. Ltd., Tokyo, Japan) cal-
brated routinely at 209 nm using a d-pantolactone solution [30].
he spectra were acquired at 25 ◦C using a 0.5 cm path length cell
t a scan speed of 20 nm/min, a bandwidth of 1.0 nm,  a response
f 0.5 s, and a resolution of 0.1 nm.  Eight scans were acquired for
ach spectrum. Following a baseline correction, the observed ellip-
icity in  (mdeg) was converted to mean residue ellipticity []
deg cm2/dmol) using the relationship [] = 100/(l × c × n), where
l” is the path length in centimeters, “c” is the millimolar peptide
oncentration, and “n” is the number of peptidic bonds. Assum-
ng a two-state model, the observed mean residue ellipticity at
22 nm (obs222) was converted into an -helix fraction (fH) using
he method proposed by Rohl and Baldwin [40].
olecular modeling
The search for templates of the Secapin sequence was performed
ith the short BLASTP algorithm [2], and the alignment was  format-
ed and input into the program. The structure of the homologous
eptide, which was experimentally solved by NMR  (PDB ID: 2KRI)
13], was selected from the Protein Data Bank (PDB) [5]. Peptide
odels were built with restraint-based modeling implemented in
ODELLER 9v11 [41] using the standard protocols for comparative
rotein structure modeling by the satisfaction of spatial restraints
36,43]. For each peptide, a total of 1000 models were created, and
he best ones were selected according to the MODELLER objec-
ive function and stereochemical analysis using PROCHECK [34].
he sequence similarity between Secapin and the template was
3% (38% identity). The ﬁnal models were selected with 90% of the
esidues in favored regions of the Ramachandran plot, with the best
alues for the overall G-factor and lower values of energy minimi-
ation. The oxidized form of Secapin was modeled; PyMOL was used
or the visualization of the Secapin model [15].
olecular dynamics simulations
The MD  simulations were performed with the GROMACS 4.5.5
oftware package [48] using the GROMOS 43A1 force ﬁeld [24] and
he ﬂexible SPC (Simple Point Charge) water mode [42]. For TFE
olecules in the simulation, the model and simulation conditions
ere applied as proposed by Fioroni et al. [21]. The simulations of
oth peptides were carried out in a cubic box containing TFE and
ater corresponding approximately to a mixture of 40:60% (v/v)
FE:water in which the minimum distance between the peptide
urface and the box face was 1.0 nm in all directions and neutralized
ith ﬁve Cl− counter ions. During the simulations, the bond lengths
ithin the peptides were constrained by the LINCS algorithm, and
he SETTLE algorithm [27] was used to constrain the water geom-
try. In the initial MD  simulation, Secapin and all the hydrogen
toms, ions, and water molecules were subjected to 500 steps of
nergy minimization by steepest descent to remove close van der
aals contacts. Both systems were then subjected to a short molec-
lar dynamics simulation with position restraints for a period of
0,000 picoseconds (ps). The ﬁnal MD simulations were performed
nder the same conditions, except that the position restraints were
emoved after an interval of 20,000 ps. The energy minimization
nd MD  were carried out under periodic boundary conditions.s 59 (2014) 42–52
The simulation was computed in the NPT ensemble at 300 K with
Berendsen temperature coupling and a constant pressure of 1 atm
with isotropic molecule-based scaling [4,12]. The temperature and
pressure were modulated using coupling techniques [4] with cou-
pling and isothermal compressibility constants of 0.01 ps (solvent
and peptide) and 6.5 × 10−5 bar−1, respectively. The electrostatic
interactions between non-ligand atoms were evaluated by the
particle mesh Ewald method [20]. The cut-off distances for the cal-
culation of the Coulomb and van der Waals interactions were 1.0
and 1.4 nm,  respectively. The convergences of the different sim-
ulations were analyzed in terms of the radius of gyration (RG),
root mean-square deviation (RMSD) from the initial structures of
the models, and types of intermolecular hydrogen bonds. All anal-
yses were performed on the ensemble of system conﬁgurations
extracted at 0.5 ps time intervals from the simulation, and the MD
trajectory collection was initiated after 1 ns of dynamics to ensure
a completely equilibrated evolution. The molecular visualization
was performed in the graphical environment PyMOL.
Hemolytic activity
Washed rat red blood cells (WRRBC) were used to evaluate the
hemolytic activity of the peptide. WRRBC were prepared by wash-
ing 50 mL  of red blood cell suspensions from Wistar rats three times
with physiological saline solution [0.85% (w/v) NaCl and 10 mM
CaCl2] and re-suspending them in 50 mL  of the same solution.
Aliquots of the WRRBC (0.5%, v/v) were then incubated at 37 ◦C
in the presence of peptide for 120 min  with gentle mixing. The
samples were then centrifuged, and the absorbance of the super-
natant was  measured at 540 nm.  The absorbance of lysed WRRBC
incubated in 1% (v/v) Triton X-100 was considered to be 100%. The
results are expressed as an average (±SD).
Mast cell degranulation activity
Mast cell degranulation was determined by measuring the
release of -d-glucosaminidase (co-localized with histamine) as
modiﬁed by De Souza et al. [18]. Mast cells were obtained as a
mixture of leukocytes by washing the peritoneum of adult Swiss
mice with a solution containing 0.877 g NaCl, 0.028 g KCl, 0.043 g
NaH2PO4, 0.048 g KH2PO4, 0.10 g glucose, 0.10 g BSA, 90 mL  of a 2 M
CaCl2 solution, and 50 L Liquemine (heparin, ROCHE) in 100 mL
water. The mast cells were incubated in the presence of peptide
for 15 min  at 37 ◦C. After centrifugation, the supernatants were
subjected to the -d-glucosaminidase assay. Brieﬂy, 50 L of the
mast cell suspension was added to 50 L of the substrate [3 mg  of
p-nitrophenyl-N-acetyl--d-glucosaminidine (Sigma) dissolved in
10 L of a 200 mM sodium citrate solution, pH 4.5] and incubated
for 6 h at 37 ◦C. The reaction was stopped by the addition of 150 L
0.2 M TRIS, pH 9.0, and the absorbance of the product was  mea-
sured at 405 nm in a microtiter plate reader (Biotrack, Amersham
Bioscience). The values were expressed as the percentage of total
-d-glucosaminidase, which was  determined from lysed mast cells
incubated with 0.1% (v/v) Triton X-100. The results were expressed
as an average (±SD). Melittin was  used as a standard compound for
positive control of this assay.
Chemotactic activity
Chemotaxis was assayed in a speciﬁc multi-chamber apparatus
(NeuroProbe, USA) using PMNL cells obtained from subcutaneous
inﬂammatory induction in Swiss mice. A special membrane with
10 m pores was introduced between the two  parts of the chemo-
taxis apparatus, which allowed the migration of leucocytes. The
total cell concentration was 105 cells/mL. The upper chambers were
ﬁlled with 200 L of PMNL suspension (2.7 × 105 cells/mL in 0.9%
eptide
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v/v) NaCl solution), while the lower chambers were ﬁlled with
00 L of physiological solution containing the peptide. A poly-
arbonate membrane (10 m pore diameter, NeuroProbe, USA)
as placed between the two chambers. The chemotaxis cham-
er was incubated at 37 ◦C for 1 h. After incubation, the cells in
he lower chambers were counted using a Neübauer chamber. The
esults were expressed as the number of migrating cells/mL and
re reported as an average (±SD). The peptide Protonectin 1-6 was
sed as standard compound for positive control of this assay.
on Frey electronic pressure-meter paw tests for mice
Hyperalgesia was induced by intraplantar (i.pl.) injection of car-
ageenan (300 g) or Secapin-2 (1, 2, 4, 10, 30 and 50 g) into
ne of the hind paws. The mice were placed in acrylic cages
12 cm × 10 cm × 17 cm high) with a wire grid ﬂoor 15–30 min
efore testing. During this adaptation period, the paws were poked
–3 times. Before paw stimulation, the animals were quiet, lacked
xploratory movements and defecation, and were not resting on
heir paws. In these experiments, we used a pressure-meter that
onsisted of a hand-held force transducer ﬁtted with a 0.5 mm2
olypropylene tip (electronic von Frey anesthesiometer, IITC Inc.,
ife Science Instruments, Woodland Hills, CA, USA). The investiga-
or was trained to apply the polypropylene tip perpendicularly to
he central area of the hindpaw with a gradual increase in pressure.
 tilted mirror below the grid provided a clear view of the animal’s
indpaw. The test consisted of poking a hindpaw to provoke a ﬂex-
on reﬂex followed by a clear ﬂinch response after paw withdrawal.
n the electronic pressure-meter test, the intensity of the stimulus
as automatically recorded when the paw was withdrawn. The
aximal force applied was 18 g. The stimulation of the paw was
epeated until the animal presented two similar measurements. If
he results were inconsistent (i.e., a great difference was observed
n the baseline response compared to the other animals in the
xperiment), another animal was used. The results are reported
s the  (delta) withdrawal threshold (g), which was  calculated by
ubtracting the values obtained after the treatment from the ﬁrst
easurement (before the treatment).
valuation of edema
Edema was induced by the i.pl. injection of carrageenan (300 g)
r Secapin-2 (1, 2, 4, 10, 30 and 50 g) into one of the hind paws. The
hickness increase (edema) of the paws up to the tibio-tarsal artic-
lation was measured using a digital pachymeter (Mitutoyo, CD-6′′
SX-B model, Brazil). The difference between the values obtained
or both paws expressed as the percent increase in paw thickness
as used as a measure of edema.
To evaluate the nociceptive activity of Secapin-2, the peptide
as dissolved in sterile saline (0.005, 0.35, 1, 2, 10 and 30 g) and
dministered by i.pl. injection into one of the hind paws of the
ice. A hypodermic 26-G needle was inserted into the skin of the
econd footpad (to avoid back ﬂow), and the tip of the needle was
ntroduced into the central area of the hindpaw in the same place
here the ﬁlaments or the tip of the pressure-meter were applied.
he nociceptive activity was evaluated at different times (0-before
he treatment, 15, 30, 60, 120, 180, 240, 360, 480 and 1440 min)
fter treatment and compared to the control. Carrageenan (Marine
olloids, 300 g) was diluted in sterile saline and was  used as a
ositive control. Sterile saline was used as a control. To evaluate
he role of prostanoids in the hyperalgesia and edema induced by
rude bee venom, the cyclooxygenase inhibitor Indomethacin was
sed. Indomethacin (Sigma, USA, 100 g) or 0.1 M Tris–HCl buffer,
H 8.0 (control) was administered by i.pl. injection to the mice
0 min  before the peptide inoculation [9]. To evaluate the involve-
ent of lipid mediators in the peptide-induced hyperalgesia,s 59 (2014) 42–52 45
Zileuton (Abbott Laboratories, Zyﬂo®, USA) (100 mg/kg, adminis-
tered orally), a lipoxygenase inhibitor, were administered 60 min
before injection of the peptides. The Zileuton was  diluted in a
solution of 10% (v/v) ethyl-alcohol. Animals injected with 10% (v/v)
ethyl-alcohol solution plus sterile saline were used as the control
group. To evaluate the involvement of leukotriene receptors,
Zaﬁrlukast (Sigma, USA) (5.0 mg/kg, administered orally) was
diluted in 0.5% dimethyl sulfoxide (DMSO, Sigma, USA).
Statistical analysis
Two-way analysis of variance (ANOVA) was  used to compare
the groups and doses over all the time points. The factors analyzed
were the treatments, time and the time versus treatment inter-
action. When a signiﬁcant time versus treatment interaction was
detected, one-way ANOVA followed by the Tukey test was per-
formed for each time point to distinguish the dose effects. One-way
ANOVA followed by the Tukey test was also used for dose–response
curves at a single time point. Results with p < 0.05 were considered
signiﬁcant.
Results
Structural characterization
The peptide fraction from Africanized honeybee venom (3.5 mg)
was fractionated by reverse-phase HPLC, resulting in the elution of
sixteen fractions (designated 1–16 in Fig. 1A). Fractions 1 and 2
consisted of histamine and serotonin, respectively (based on chro-
matograms developed in presence of standard compounds; not
shown results); fractions 4–6 and 8–10 were determined to be very
low abundant venom components not yet characterized, while frac-
tions 11 and 14 corresponded to Apamin and Melittin, respectively
(based on chromatograms developed in presence of standard com-
pounds; not shown results). The peptide component of fraction 7
(empty arrow, Fig. 1A) was  subjected to mass spectrometric analy-
sis revealing an ESI mass spectrum characterized by the molecular
ions of m/z 719.14 as [M+H]+4, and m/z 958.52 as [M+H]+3 (Fig. 1B).
Fig. 1C shows the envelope of peaks at monoisotopic resolution
for the quasi-molecular ion at m/z 719.14 as [M+H]+4; the trans-
formation of these data revealed that the peptide component of
fraction 7 has a molecular mass of 2872.58 Da in the oxidized form
(Fig. 1C). Considering that the mass spectrum indicated that the
peptide component was highly pure, it was subjected to amino acid
sequencing using automated Edman degradation chemistry, which
revealed the following sequence: YIIDVPPRCPPGSKFVHKRCRVIVP.
The sequence of this peptide revealed the presence of two cys-
teine residues, which raised the possibility of a disulﬁde bridge
formed by the thiol groups of the cysteine side chains under nat-
ural conditions. To test this possibility, the peptide was reduced
by dithiothreitol treatment, and the mass spectra was reacquired,
revealing a molecular of 2874.58 Da (data not shown), due to the
incorporation of two  hydrogens (one for each thiol group); this
result conﬁrms the existence of a disulﬁde bridge between the two
cysteine residues. The molecular mass of 2874.58 Da for the nat-
ural peptide in its reduced form is consistent with an amidated
C-terminal residue and the presence of an intramolecular disulﬁde
bond; the complete primary structure of the peptide is shown in
Fig. 1D.
Because the secondary structure is important for understanding
the biological activities of the peptide, it was initially investigated
using CD spectroscopy. The CD spectra of the oxidized form of the
fraction 7 peptide obtained in water, in 40% (v/v) TFE, and in the
presence of SDS below and above the CMC  (at 165 M and 8 mM
SDS, respectively) are shown in Fig. 2.
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Fig. 1. (A) Chromatography proﬁle of the peptide fractions of venom from Africanized A. mellifera under RP-HPLC using a Capcell Pack C-18 UG120 column (10 mm × 250 mm,
5  m,  Shisheido) under a linear gradient from 5 to 60% (v/v) MeCN/H2O [containing 0.1% (v/v) TFA] at a ﬂow rate of 2.0 mL/min for 60 min  and monitored by UV absorption at
214  nm with a UV-DAD detector (Shimadzu, mod. SPD-M10A). The fractions were manually collected in glass vials and dried using a lyophilizer. The elution was monitored
by  measurement of the UV absorption at UV 214 nm.  Fraction 7, containing the Secapin-2 peptide, is designated by an empty arrow. (B) ESI mass spectrum obtained in the
positive mode for fraction 7; the peptide was detected as molecular ions of m/z 719.14 as [M+H]+4, and m/z 958.52 as [M+H]+3. (C) The insert is showing the envelope of peaks
of  the molecular ion at m/z 719.14 with monoisotopic resolution, and the transformation of the ESI/MS data revealing that the peptide has a molecular mass of 2872.58 Da
in  its oxidized form. (D) Amino acid sequence of Secapin-2 isolated from the venom of Africanized A. mellifera showing the connectivity of the disulﬁde bridge.
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fig. 2. CD spectra of Secapin obtained at 20 M at 25 ◦C in the presence of water,
 mM SDS and 40% (v/v) TFE. No smoothing has been applied.
The spectrum of the peptide in water (Fig. 2) is characteris-
ic of an unordered conformation. In a medium composed of 40%
v/v) TFE and also in 8 mM SDS, two negative dichroic bands were
bserved, which is consistent with the induction of some -helical
onformations under these conditions. Nevertheless, the two neg-
tive dichroic bands observed for the fraction 7 peptide (208 and
22 nm)  are characteristic of an -helix. SDS below the CMC  tends
o induce -sheet conformations and mimics the core environment
f proteins [6]. Sequences with either lower helical propensities
r which show a tendency to form aggregates will deviate from
he helical pattern. The CD spectrum obtained in this environment
learly indicated that the fraction 7 peptide has reduced helical
ontent. Table 1 shows the molar ellipticity ([222]) and the -
elical fraction (fH*) calculated according to the two-state model
40]. In addition, the CD spectra, in different environments, were
nalyzed by spectral deconvolution using the CONTIN program and
he protein database SMP56 within the CDPro package. The analy-
es showed slightly higher helical contents (regular and distorted
-helical content) compared to those obtained with the two-state
odel. These analyses also showed that the peptide possesses
any unordered and turn structures.
The molecular model of the fraction 7 peptide is shown in Fig. 3;
he analysis of the Ramachandran plot for this molecular model (Fig.
 in supplementary content) revealed that more than 90% of the
esidues lie in the most favorable regions. These results indicate
hat the model is adequate for structural studies. The molecular
odel of the peptide possesses a small helix that is maintained and
ost likely stabilized by the disulﬁde bridge (Fig. 3).
able 1
econdary structure evaluation of Secapin in different environments: water, 40%
v/v) TFE solution, 165 M SDS, and 8 mM SDS Molar ellipticity ([]222) and -helix
ractions (fH*) were calculated according to the two-state model [40], and the frac-
ion content of helical (H), strand (S) and unordered (Unrd) structures were obtained
rom the spectral deconvolution using the package CDPro (CONTIN, SMP56).
Condition []222 fH* H S Unrd
Water 1260 ± 38 rc - - -
40%  (v/v) TFE -3350 ± 68 0.12 0.15 0.37 0.39
165  M SDS -124 ± 75 - 0.03 0.45 0.22
8  mM SDS -2460 ± 37 0.11 0.14 0.21 0.27Fig. 3. Representation of the 3-D model of the Secapin-2 peptide.
Despite the fact that the molecular model is considered ade-
quate by the criteria considered above, it is a static model. To obtain
a more realistic idea of the structure of this peptide, the model
above was subjected to molecular dynamics (MD) analysis. The
purpose of performing molecular dynamics was to investigate the
stability of the secondary structure of the peptide; this analysis was
performed by evaluating different variables:
(i) The root-mean-square deviation (RMSD) of the positions for all
backbone C- atoms as a function of simulation time (Fig. 4A).
The RMSD values for the C-  atoms of the peptide initially
increased rapidly during the MD simulation (until 8000 ps).
However, this increase was followed by a period of rela-
tive stability for most of the remaining simulation time. The
RMSD values for the C- atoms of the peptide remained stable
throughout the MD  simulation, suggesting that 20 ns of unre-
strained simulation were sufﬁcient to stabilize the peptide.
(ii) The radius of gyration is the root-mean-square distance of the
atoms in relation to the x, y and z axes of a speciﬁc molecule, and
it can be indicative of the size and compactness of a molecule.
Fig. 4B shows that the peptide had a radius of gyration of
0.95 nm after 20 ns simulation. These results indicate that the
presence of the disulﬁde bridge stabilizes the peptide into a
compact molecular structure.
(iii) Analysis of the potential energy (Fig. 4C) shows that the pep-
tide reached equilibrium and did not exhibit any asymptotic
behavior.
The surface charge representation of the peptide (Fig. 5) shows
that it has a compact structure characterized by two  surfaces pre-
senting a central region of positive residues that is located between
two opposite regions of negative charge.
Functional characterization
Because nothing is known about the pharmacological and physi-
ological effects of the fraction 7 peptide present in the crude venom
of A. mellifera, one of the goals of the present investigation was
to determine whether this peptide exhibits some of the biological
activities typical of the polycationic peptides from Hymenoptera
venoms. To this end, the peptide was  assayed for mast cell degra-
nulation, hemolysis, and chemotaxis of PMLNs but did not exhibit
any of these activities (Figs. 2–4 in Supplementary content).
Another objective of the present study was to investigate the
involvement of this peptide in the induction of the hyperalge-
sia/analgesia and inﬂammation/anti-inﬂammation processes. For
this purpose, different doses of Secapin (0.005, 0.35, 1, 2, 10 and
30 g) were injected into mice by intraplantar (i.pl.) adminis-
tration, and the mice were tested for mechanical hyperalgesia
(through the electronic von Frey) at different times (15, 30, 60, 120,
180, 240, 360, 480 and 1440 min) after the peptide administration.
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Fig. 5. Structural model of Secapin-2 as a charge surface representation in two  dif-ig. 4. Molecular dynamics simulations of Secapin. (A) Root mean-square deviation
RMSD), (B) radius of gyration (Rg), and (C) potential energy.
he control group animals were injected with the same vehicle
saline – S) that was used to dilute the peptide under the same
xperimental conditions. The positive control animals received i.pl.
njection of carrageenan (Cg) at a dose of 300 g.
The results show that in the ﬁrst 15 min  after the injection of the
raction 7 peptide there was a signiﬁcant peak of pain (higher than
hat caused by the carrageenan); after this time, a decrease in pain
hreshold was observed, which was characterized as hypernocicep-
ion (hyperalgesia) (Fig. 6A, C and E). However, this hyperalgesia
ersisted for 1440 min  when the peptide dose was 10 or 30 g
Fig. 6A), 480 min  when it was 1, 2, 0.005 or 0.35 g (Fig. 6C and
). The animals treated with carrageenan (positive control) exhib-
ted a hyperalgesic effect for more than 1440 min  (Fig. 6A, C and E).
n addition, no signiﬁcant differences were observed in the noci-
eptive threshold of the control group animals (Fig. 6A, C and E).
In addition to hyperalgesia, the edema activity of the peptide
as also evaluated. The results showed that 10 or 30 g of the
eptide induced a signiﬁcant increase in paw thickness (compared
ith carrageenan) from 15 to 30 min  after the peptide injection;
fter 30 min, the edema decreased continuously up to 240 min
Fig. 6B). The paw thickness induced by peptide doses between
 and 0.005 g was lower than that induced by carrageenan, andferent molecular surfaces. Negative residues are shown in dark gray (red in the
web version), and positive residues are shown in gray (blue in the web version),
hydrophilic in light gray and hydrophobic in white.
decreased slowly until 240 or 360 min, depending on the peptide
dose (Fig. 6C and F).
Because the peptide induced hyperalgesia and edema effects,
the next objective was to investigate the involvement of
prostanoids and lipid mediators derived from the cyclooxygen-
ase and lipoxygenase pathways, respectively, in these effects. Mice
were injected with the fraction 7 peptide (0.35 g i.pl.) and treated
with Indomethacin (Indo, 100 g i.pl.), a cyclooxygenase path-
way inhibitor, or Zileuton (Zil, 100 mg/kg orally in 500 L), a
lipoxygenase pathway inhibitor, and were tested for mechanical
hyperalgesia and edema formation.
The results showed that Zileuton suppressed the peptide-
induced hyperalgesia at 15 and 60 min  when compared with the
control group. On the other hand, Indomethacin did not suppress
this effect (Fig. 7A and C).
Zileuton also suppressed the peptide-induced edema; however,
only partial suppression was  observed 15 min  after administration
of the peptide, while complete suppression was observed 60 min
after peptide administration (Fig. 7B and D). On the other hand,
Indomethacin did not suppress the edema, which was not sig-
niﬁcantly different in treated animals compared with the control
group.
Because the results presented here showed that Zileuton sup-
pressed the peptide-induced hyperalgesia and edema, it became
important to study further the mechanisms of action induced by
this peptide. For this purpose, Zaﬁrlukast, a leukotriene recep-
tor antagonist, was  injected into mice (5 mg/kg in 300 L of 0.5%
(v/v) DMSO orally). The results indicated that Zaﬁrlukast partially
blocked the hypernociceptive effect of the peptide 15 min  after
peptide administration when compared with the control group
(Sec + S) (Fig. 8A). The group treated with 0.5% (v/v) DMSO vehicle
(DMSO + Sec) showed no difference from the control group (Sec + S)
(Fig. 8A). Zaﬁrlukast also partially inhibited the edema thickness
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Fig. 6. Evaluation of the hyperalgesic and edematogenic effects of Secapin-2. The paw threshold was estimated using an electronic von Frey device. The force needed to
induce  paw withdrawal was recorded as the pain threshold represented by delta () (A, C, and E). Edematogenic effects were evaluated using a digital caliper pachymeter
(B,  D, and F). The data were obtained at time 0 and at 15, 30, 60, 120, 180, 240, 360, 480 and 1440 min  after Secapin-2 administration (10 and 30 g i.pl. shown in A and B, 1
and  2 g i.pl. shown in C and D, and 0.35 and 0.005 g i.pl. shown in E and F) or carrageenan administration (Cg, 300 g i.pl.). The control group consisted of animals injected
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iith  sterile saline (S). The results are expressed as the mean ± SEM of 5 animals pe
S)  group; #p < 0.001, a signiﬁcant difference compared with the mean values of the
Fig. 8A). The group treated with 0.5% (v/v) DMSO (Sec + DMSO)
howed no signiﬁcant difference from the control group (Sec + S)
Fig. 8B).
iscussion
The peptide puriﬁed from fraction 7 of the Africanized honey-
ee venom had a sequence (YIIDVPPRCPPGSKFVHKRCRVIVP-NH2)
ery similar to that of Secapin, which was originally isolated from
 European species of A. mellifera (YIIDVPPRCPPGSKFIKNRCRVIVP-
H2) [35,49] and related to a variant form of this peptide
solated from the venom of A. mellifera in China named Secapin-1p. *p < 0.001, a signiﬁcant difference compared with the mean values of the saline
geenan (Cg) group.
(YIINVPPRCPPGSKFVKNKCRVIVP-NH2) [37]; therefore, the peptide
isolated from fraction 7 was designated Secapin-2.
The polymorphic changes observed between Secapin-2 and
Secapin included substitutions at amino acids 16–18, while the dif-
ferences between Secapin-1 and -2 were substitutions at 17–19.
All of these different forms of Secapin shared a disulﬁde bridge
between the Cys 9 and Cys 20 residues.
The secondary structure of Secapin-2 was investigated by CD
spectroscopy; apparently, this peptide has reduced helical content
in anisotropic and membrane-mimetic environments. This analysis
also showed that Secapin-2 has relatively high strand structure con-
tent. A structurally reliable molecular model was developed using
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Fig. 7. Involvement of eicosanoids in the hyperalgesic and edematogenic effects of Secapin-2. The paw threshold was estimated using an electronic von Frey device. The force
needed to induce paw withdrawal was recorded as the pain threshold represented by delta () (A and C). Edematogenic effects were evaluated using a digital pachymeter
(B  and D). The data were obtained at time 0, 15 min  (A and B) and 1 h (C and D) after Secapin-2 administration (30 g i.pl.). Indomethacin (I, 100 g i.pl.) and Zileuton (Z,
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w00  mg/kg, orally in 500 L) were administered 30 min  and 1 h before peptide injec
he  results are expressed as the mean ± SEM of ﬁve animals per group. *p < 0.001, a
lgorithms of structural biology and molecular dynamics; accord-
ngly, the structure of Secapin-2 appears to be compact, stable,
nd stabilized by the disulﬁde bridge. A careful observation of this
odel revealed that the molecule has two easily distinguishable
urfaces (Fig. 5), which are characterized by positive charges at the
enter of these surfaces that are ﬂanked by two small regions of
egative charge.
A structural comparison between the secondary structures of
he peptides Apamin, Tertiapin and Secapin, which were isolated
rom honeybee venom, showed that these peptides have a com-
on  structural motif that is composed of a -turn covalently linked
o a short -helical segment by one disulﬁde bond. Apamin and
ertiapin have two copies of this motif as both peptides have two
ntramolecular disulﬁde bridges [28]. The molecular model devel-
ped in the present study also shows this motif (Fig. 3).
Some studies have reported different activities than those found
or Secapin for A. mellifera crude venom and/or some of the peptide
oxins isolated from this venom [10,44].
Lariviere and Melzack [32] published the ﬁrst experimental data
sing A. mellifera crude venom in an animal model, demonstrating
hat the nociceptive activity of this venom was dose dependent
nd lasted up to 60 min. Chen et al. [10] also reported a hyperalgesic
ffect caused by bee venom when injected into the hind paw of rats,
eporting that this effect may  be different depending on the noxious
timulus used. For example, mechanical stimulus caused a drop
f 48% in the nociceptive threshold of the animal, while thermal
timulus caused a drop of 42% in this threshold. Importantly, this
tudy also reported that the hyperalgesic effect was long lasting
ecause 0.2 mg  of the crude venom caused hyperalgesia that lasted
or 3 days.
Brigatte et al. [8] studied the hyperalgesic and edematogenic
ffects of Melittin using a mechanical stimulus (electronic von Frey)
n mice. This study reported that the hyperalgesic effect persisted
or more than 8 h after administration for all peptide doses assayed,
hile the edema was long lasting only at high doses of Melittin.espectively. The control group consisted of animals injected with Secapin-2/Saline.
cant difference compared with the mean values of the Secapin-2/Saline group.
In the present study, the duration of the hyperalgesia and edema
were evaluated; the hyperalgesic effect persisted for up to 24 h at
doses of 1 and 2 g, while the effect lasted only up to 8 h at doses of
10 and 30 g. These results are similar to those previously reported
for Melittin [8]. The edematogenic effect was signiﬁcantly different
in the treated groups compared with the control group, persisting
longer than 19 h at doses of 30 and 50 g Secapin-2.
Once the effect of Secapin-2 was  characterized by the occur-
rence of hyperalgesia and edema, the next step was to evaluate the
chemical mediators involved in these processes. For this purpose,
animals were treated with Indomethacin and Zileuton (nonspeciﬁc
antagonists of cyclooxygenase and lipoxygenase, respectively).
The results of the present study showed a partial suppression
of hyperalgesia and edema in the animals treated with Zileuton
15 min  after Secapin-2 injection and complete suppression 60 min
after peptide injection. The animals treated with Indomethacin
showed no signiﬁcant effect compared with the control group.
Like Secapin-2, Melittin-induced hyperalgesic and edemato-
genic effects were previously reported to involve lipid mediators
[8]. On the other hand, prostanoids were shown to mediate the
pain and inﬂammation induced by crude bee venom because
Indomethacin reversed these effects [33].
After observing that Zileuton reversed the hyperalgesia and
edema induced by Secapin-2, the next step was to assay the ability
of Zaﬁrlukast to suppress pain and edema. As observed for Zileu-
ton, Zaﬁrlukast partially reversed the actions induced by Secapin-2,
indicating that leukotriene receptors must mediate the action of
this peptide.
Taken together, these data showed that Secapin-2 does not
induce hemolytic activity, mast cell degranulation, or PMNL
chemotaxis; however, it does induce hyperalgesia and edema
mediated by leukotrienes. In comparison, the peptide Paulistine
was recently reported; this peptide was  isolated from the venom
of the social wasp P. paulista, had a structural motif similar
to that described above for Secapin-2, and caused hyperalgesia
D. Mourelle et al. / Peptide
Fig. 8. Involvement of leukotriene receptors on the hyperalgesic and edemato-
genic effects of Secapin-2. The paw threshold was  estimated using an electronic
von  Frey device. The force needed to induce paw withdrawal was recorded as the
pain threshold represented by delta () (A). Edematogenic effects were evaluated
using a digital pachymeter (B). The data were obtained at time 0, and 15 min  after
Secapin-2 administration (30 g i.pl.). Zaﬁrlukast (Zaﬁr, 5 mg/kg, orally), an antago-
nist of the leukotriene receptor, was administered before Secapin-2 administration
(Sec + Zaﬁr). The reference groups consisted of animals injected with Secapin-
2/saline and Secapin-2/DMSO. The results are expressed as the mean ± SEM of ﬁve
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y interacting with the receptors of lipid mediators involved
n the cyclooxygenase type II pathway [26]. The mechanism of
ction of Secapin-2 on leukotrienes pathway is unknown, but
aking into account of the inhibitory effects of Zileuton and
aﬁrlukast in the inﬂammatory action caused by the peptide,
t may  be considered that: (i) Zileuton is an inhibitor of the
-lipoxygenase (5-LO), which catalyzes the ﬁrst two catalytic
teps of this pathway [52]; (ii) Zaﬁrlukast blocks the action of
he cysteinyl leukotrienes on CysLT1 receptors [53]; (iii) There-
ore, the site(s) of interaction with Secapin-2 must located in
he metabolic steps between the 5-LO and the CysLT1 recep-
ors.
onclusion
In conclusion, the present investigation led to a better under-
tanding of the inﬂammation and pain induced by honeybee
enom. Although the existence of the Secapin peptide (and its
nalogs) in honeybee venom has been known for approximately 38
ears, almost nothing has been known about the pharmacology of
his peptide until now. The present work has pioneered the func-
ional characterization of this toxin and revealed that Secapin-2
nduces inﬂammation and pain through the lipoxygenase pathway.
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